Alpha heavy chain disease: report of two cases

Advanced breast-cancer - a randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-Fluorouracil.

Oncology reports·2011

The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer.

Oncology reports·2011

A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma.

International journal of oncology·2011

Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors.

International journal of oncology·2011

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Leukemia·2008

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome.

Arthritis and rheumatism·2008

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Haematologica·2026

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Haematologica·2026

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Haematologica·2026

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Haematologica·2026

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Haematologica·2026

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Haematologica·2026

Nanoparticle-enabled CD40 silencing programs immune tolerance via a DC-Treg-Breg axis in autoimmune myocarditis.

Materials today. Bio·2026

Infliximab-Associated IgA Vasculitis Masquerading as Crohn's Disease Relapse: Leukocytoclastic Vasculitis Confirmed on Duodenal Biopsy - A Case Report.

Inflammatory intestinal diseases·2026

Ethosuximide-induced lupus erythematosus: Unveiling a rare adverse reaction through systematic review.

Epilepsy & behavior reports·2026

Case Report: Elderly anti-GBM antibody disease with diffuse non-hereditary glomerular basement membrane thinning of uncertain etiology.

Frontiers in medicine·2026

Autoimmune thyroiditis in pregnancy: epidemiology, clinical impact, and contemporary management challenges.

Journal of medicine and life·2026

TREM2 as a central immunometabolic hub in Alzheimer's disease: linking microglial states, lipid stress, and disease-stage-specific intervention.

Frontiers in immunology·2026

Related Experiment Videos

Alpha heavy chain disease: report of two cases

Related Concept Videos

Advanced breast-cancer - a randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-Fluorouracil.

The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer.

A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma.

Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors.

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome.

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Nanoparticle-enabled CD40 silencing programs immune tolerance via a DC-Treg-Breg axis in autoimmune myocarditis.

Infliximab-Associated IgA Vasculitis Masquerading as Crohn's Disease Relapse: Leukocytoclastic Vasculitis Confirmed on Duodenal Biopsy - A Case Report.

Ethosuximide-induced lupus erythematosus: Unveiling a rare adverse reaction through systematic review.

Case Report: Elderly anti-GBM antibody disease with diffuse non-hereditary glomerular basement membrane thinning of uncertain etiology.

Autoimmune thyroiditis in pregnancy: epidemiology, clinical impact, and contemporary management challenges.

TREM2 as a central immunometabolic hub in Alzheimer's disease: linking microglial states, lipid stress, and disease-stage-specific intervention.

Related Experiment Videos

Alpha heavy chain disease: report of two cases

Related Concept Videos

Related Articles